Home / Central Data Catalog / FRESH-PEF2526-EN
central

Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device (ZOMAJET)

France, 2007 - 2011
Reference ID
FRESH-PEF2526-en
Producer(s)
Farah;BAHBAH
Metadata
DDI/XML JSON
Study website Interactive tools
Created on
Feb 18, 2026
Last modified
Feb 18, 2026
Page views
40
  • Identification
  • Scope
  • Coverage
  • Producers and sponsors
  • Study authorization
  • Sampling
  • Survey instrument
  • Data collection
  • Study activities
  • Data Access
  • Contacts

    • Identification

    Survey ID number

    FRESH-PEF2526-en
    Title

    Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device (ZOMAJET)
    Abbreviation or Acronym

    ZOMAJET
    Country
    Name Country code
    France fr
    Kind of Data

    ['Clinical data','Paraclinical data (non-biological)','Paraclinical data (non-biological) : Anthropometry','Biological data','Participant-reported health data']
    Unit of Analysis

    Individuals

    Scope

    Topics
    Topic Vocabulary
    Endocrinology health theme
    Paediatrics health theme
    Healthcare system determinants: Use of care health determinant
    Healthcare system determinants health determinant
    Keywords
    Somatropin zomacton zomajet vision X Zomajet 2 vision

    Coverage

    Universe

    {"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Child, Preschool (2 to 5 years)","concept":{"vocab":"MeSH","vocabURI":"D002675"}},{"value":"Child (6 to 12 years)","concept":{"vocab":"MeSH","vocabURI":"D002648"}},{"value":"Adolescent (13 to 18 years)","concept":{"vocab":"MeSH","vocabURI":"D000293"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"All patients, meeting the criteria of the Therapeutic Information Sheet (growth hormone deficiency or Turner's syndrome), for whom is initiated a treatment with Zomacton® 4 mg with the Zomajet® 2 Vision transjector or with Zomacton® 10 mg with the Zomajet® Vision X transjector when the latter has received its marketing authorization.","clusion_E":""}

    Producers and sponsors

    Primary investigators
    Name
    Farah;BAHBAH
    Producers
    Name Role
    FERRING SAS sponsor
    Funding Agency/Sponsor
    Name
    FERRING SAS

    Study authorization

    Agency
    Agency name
    CNIL

    Sampling

    Sample frame

    Unit Type

    ['Through organizations (health services or institutions, schools, businesses, etc.)']
    Sampling Procedure

    ['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']

    Survey instrument

    Questionnaires

    Access on specific project only
    Methodology notes

    Observational Study

    Data collection

    Dates of Data Collection
    Start End
    2007-01-01 2011-01-01
    Mode of data collection
    • {"concept":{"vocabURI":"Interview","vocab":"CESSDA"},"value":"Interview with the participant (including clinical)"}

    Study activities

    Study activities
    Type
    primary evaluation
    Description
    Health event/morbidity Health care consumption and services

    Data Access

    Access conditions

    For further information on the ZOMAJET study, please contact: Dr Philippe NIEZ
    Availability Status

    {"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}

    Contacts

    Contacts
    Name Email
    Farah;BAHBAH Farah.Bahbah@ferring.com
    Back to Catalog